SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-100960
Filing Date
2024-04-18
Accepted
2024-04-18 17:25:53
Documents
19
Period of Report
2024-04-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d816580d8k.htm   iXBRL 8-K 28970
2 EX-1.1 d816580dex11.htm EX-1.1 203129
3 EX-5.1 d816580dex51.htm EX-5.1 10504
4 EX-99.1 d816580dex991.htm EX-99.1 5100
5 EX-99.2 d816580dex992.htm EX-99.2 9042
9 GRAPHIC g816580dsp_p1.jpg GRAPHIC 6778
10 GRAPHIC g816580dsp_p2.jpg GRAPHIC 3305
  Complete submission text file 0001193125-24-100960.txt   454636

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA itci-20240417.xsd EX-101.SCH 2896
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20240417_lab.xml EX-101.LAB 17236
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20240417_pre.xml EX-101.PRE 10843
22 EXTRACTED XBRL INSTANCE DOCUMENT d816580d8k_htm.xml XML 3481
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 24855110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)